Legal & General Group
CTMX icon

Legal & General Group’s CytomX Therapeutics CTMX Stock Holding History

Legal & General Group’s Portfolio CTMX Stock Details CTMX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$462K Sell
123,313
-18,580
-13% -$70.9K ﹤0.01% 2422
2026
Q1 		$667K Buy
+141,893
New +$720K ﹤0.01% 2277
2022
Q2 		– Sell
-8,372
Closed -$23K – 3553
2022
Q1 		$23K Buy
8,372
+316
+4% +$1.21K ﹤0.01% 3200
2021
Q4 		$35K Sell
8,056
-11,472
-59% -$67.2K ﹤0.01% 3106
2021
Q3 		$99K Buy
19,528
+9,942
+104% +$53.2K ﹤0.01% 2844
2021
Q2 		$60K Buy
9,586
+870
+10% +$6.77K ﹤0.01% 2890
2021
Q1 		$68K Buy
8,716
+2,001
+30% +$15.8K ﹤0.01% 2730
2020
Q4 		$44K Hold
6,715
– – ﹤0.01% 2836
2020
Q3 		$44K Sell
6,715
-1,947
-22% -$14.4K ﹤0.01% 2738
2020
Q2 		$72K Buy
8,662
+389
+5% +$3.61K ﹤0.01% 2616
2020
Q1 		$63K Sell
8,273
-2,549
-24% -$17.8K ﹤0.01% 2530
2019
Q4 		$90K Buy
10,822
+1,723
+19% +$11.6K ﹤0.01% 2627
2019
Q3 		$67K Hold
9,099
– – ﹤0.01% 2645
2019
Q2 		$102K Buy
9,099
+757
+9% +$7.94K ﹤0.01% 2517
2019
Q1 		$89K Hold
8,342
– – ﹤0.01% 2524
2018
Q4 		$126K Buy
8,342
+1,306
+19% +$19.4K ﹤0.01% 2409
2018
Q3 		$130K Buy
7,036
+934
+15% +$21.3K ﹤0.01% 2439
2018
Q2 		$139K Buy
6,102
+984
+19% +$25.1K ﹤0.01% 2395
2018
Q1 		$146K Sell
5,118
-2,128
-29% -$60.7K ﹤0.01% 2371
2017
Q4 		$155K Hold
7,246
– – ﹤0.01% 2412
2017
Q3 		$131K Buy
7,246
+798
+12% +$12.5K ﹤0.01% 2498
2017
Q2 		$101K Buy
6,448
+1,434
+29% +$21.6K ﹤0.01% 2601
2017
Q1 		$86K Sell
5,014
-247
-5% -$3.25K ﹤0.01% 2624
2016
Q4 		$58K Buy
5,261
+1,606
+44% +$19.5K ﹤0.01% 2842
2016
Q3 		$58K Hold
3,655
– – ﹤0.01% 2444
2016
Q2 		$36K Buy
+3,655
New +$41.7K ﹤0.01% 2636

Other funds holding CTMX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return

Legal & General Group's CTMX Position: Q2 2026 in Review

Legal & General Group reduced its CytomX Therapeutics (CTMX) stake by 13% in Q2 2026, selling an estimated $70.9K and leaving 123,313 shares worth $462K. The position accounts for ﹤0.01% of the portfolio, ranked #2422.

Legal & General Group first reported a position in CTMX in Q2 2016 and has held it in 26 quarters since. The position peaked at $667K in Q1 2026. 178 funds tracked by Wall St. Rank hold CTMX as of Q2 2026.

  • Legal & General Group held 123,313 shares of CytomX Therapeutics worth $462K as of Q2 2026.
  • Legal & General Group sold 18,580 CytomX Therapeutics shares in Q2 2026, an estimated $70.9K.
  • CytomX Therapeutics made up ﹤0.01% of Legal & General Group's portfolio in Q2 2026, its #2422 holding.
  • Legal & General Group first reported a position in CytomX Therapeutics in Q2 2016 and has held it in 26 quarters since.
  • Legal & General Group's CytomX Therapeutics position peaked at $667K in Q1 2026.
  • 178 funds tracked by Wall St. Rank held CytomX Therapeutics as of Q2 2026.

Based on Legal & General Group's 13F filing for Q2 2026, filed 14 Aug 2026.